Patents Examined by Anne Holleran
  • Patent number: 9850313
    Abstract: Methods and compositions for treating cancer, particularly breast cancer, are disclosed.
    Type: Grant
    Filed: August 5, 2013
    Date of Patent: December 26, 2017
    Assignee: Board of Regents of the University of Nebraska
    Inventors: Vimla Band, Hamid Band, Sameer Mirza
  • Patent number: 9845356
    Abstract: The present invention is based, in part, on the identification of novel antibodies that have binding affinity for both PD-L1 and PD-L2 and methods of using same. In one aspect, an isolated monoclonal antibody, or antigen-binding fragment thereof, which specifically binds both PD-L1 and PD-L2, is provided. In one embodiment, both PD-L1 and PD-L2 are human PD-L1 and human PD-L2.
    Type: Grant
    Filed: August 2, 2013
    Date of Patent: December 19, 2017
    Assignees: Dana-Farber Cancer Institute, Inc., President and Fellows of Harvard College
    Inventors: Gordon J. Freeman, Arlene H. Sharpe
  • Patent number: 9822169
    Abstract: The invention includes the use of the HE/HE4a markers to assess ovarian cancer in a subject. Included also are compositions and methods of using HE/HE4a marker for diagnosis, grading and staging of ovarian cancers, determining prognosis and treatment effectiveness of a subject who has been diagnosed with ovarian cancer.
    Type: Grant
    Filed: February 17, 2011
    Date of Patent: November 21, 2017
    Assignees: PACIFIC NORTHWEST DIABETES RESEARCH INSTITUTE, FUJIREBIO DIAGNOSTICS, INC.
    Inventors: Ingegerd Hellstrom, Karl-Erik Hellstrom, John Raycraft, Christian Fermér, Eva Roijer
  • Patent number: 9803025
    Abstract: Described herein are materials and methods for treating subjects having a HER-3 associated disease, by administering a first agent that binds to HER-3, in combination with a second agent that binds and/or inhibits another member of the HER family. The first and the second agent may be a biologic, such as an antigen-binding protein, or a small molecular tyrosine kinase inhibitor, for example.
    Type: Grant
    Filed: April 25, 2013
    Date of Patent: October 31, 2017
    Assignees: AMGEN, INC., Daiichi Sankyo Europe GmbH
    Inventors: Thore Hettmann, Daniel J. Freeman, Robert Radinsky
  • Patent number: 9783615
    Abstract: The present invention provides MT4-MMP inhibitor and EGFR inhibitor for use in the treatment of cancer, wherein said MT4-MMP inhibitor and EGFR inhibitor are different from each other. MT4-MMP (MMP-17) is a glycosylphosphatidyl inositol (GPI) anchored MMP produced by cancer cells that promotes tumor vascularization and metastases. The present invention found that MT4-MMP expression promotes cancer cell proliferation. These effects involve retinoblastoma protein (Rb) inactivation, cyclin dependent kinase CDK4 activation and Epidermal Growth Factor Receptor (EGFR) signaling. Co-immuno-precipitations indicate the existence of protein complexes harboring MT4-MMP and EGFR. The present invention further found a novel mechanism of MT4-MMP action through an outside-in signaling involving EGFR. An unexpected crosstalk between an MMP and EGFR was identified and recognized as a key driver of cancer cell biology.
    Type: Grant
    Filed: September 2, 2013
    Date of Patent: October 10, 2017
    Assignee: UNIVERSITE DE LIEGE
    Inventors: Agnès Noel, Nor Eddine Sounni, Alexandra Paye
  • Patent number: 9725511
    Abstract: The invention relates to anti-HER3/HER4 antigen binding proteins, e.g. anti-HER3/HER4 antibodies, that bind to the beta-hairpin of HER3 and the beta-hairpin of HER4, methods for selecting these antigen binding proteins, their preparation and use as medicament.
    Type: Grant
    Filed: November 6, 2013
    Date of Patent: August 8, 2017
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Birgit Bossenmaier, Guy Georges, Michael Gerg, Gerhard Niederfellner, Christian Scholz, Michael Schraeml
  • Patent number: 9725512
    Abstract: The invention relates to anti-HER3 antigen binding proteins, e.g. anti-HER3 antibodies, that bind to the beta-hairpin of HER3, methods for selecting these antigen binding proteins, their preparation and use as medicament.
    Type: Grant
    Filed: November 6, 2013
    Date of Patent: August 8, 2017
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Birgit Bossenmaier, David Casagolda Vallribera, Guy Georges, Michael Gerg, Gerhard Niederfellner, Christian Scholz, Michael Schraeml
  • Patent number: 9687568
    Abstract: This invention relates to a composition of a non-labeled monoclonal antibody binding to a tumor antigen and a second monoclonal antibody labeled with a NIR fluorescence label, binding to the same tumor antigen, wherein the first and second antibody exhibit no cross reactivity. The composition can be used for the treatment of patients suffering of solid tumors which are associated with an overexpression of such a tumor antigen. The invention further relates to a the co-administration of said first and second antibody as wells as to a method of acquiring a NIR fluorescence images of such tumors or the patients suffering from such tumors during the treatment of said patient with such composition.
    Type: Grant
    Filed: August 7, 2013
    Date of Patent: June 27, 2017
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Max Hasmann, Helmut Lenz, Werner Scheuer
  • Patent number: 9688738
    Abstract: The present invention describes methods and pharmaceutical compositions for the treatment of cancer in mammals, more particularly in human subjects. More specifically, the invention concerns anti-tumor vaccines based upon plasmid DNA and/or genetic vectors carrying a codon-usage optimized sequence and coding for a mutant form of the ErbB-3 receptor. Furthermore, the invention refers to monoclonal antibodies directed against the ErbB-3 receptor, obtained using these methods and capable to block its activity in cancer cells.
    Type: Grant
    Filed: November 2, 2011
    Date of Patent: June 27, 2017
    Assignee: TAKIS S.R.L.
    Inventors: Luigi Aurisicchio, Gennaro Ciliberto, Rita Mancini, Emanuele Marra, Guiseppe Roscilli
  • Patent number: 9683265
    Abstract: The subject invention discloses a method for determining the prognosis and probable clinical course of a subject diagnosed with B-CLL. Specifically, the invention involves comparing CD38 expression in a biological sample from the subject containing B-CLL cells to a baseline level of CD38 expression, wherein an elevated level of CD38 expression in relation to the baseline level of CD38 expression may indicate poor prognosis or aggressive course of disease in the subject. Also disclosed is a method for determining whether the Ig V genes of the B-CLL cells of a B-CLL patient are mutated, comprising comparing CD38 expression in a biological sample from the subject containing B-CLL cells to a baseline level of CD38 expression, wherein a lower level of CD38 expression in relation to the baseline level indicates IG V gene mutation.
    Type: Grant
    Filed: June 29, 2016
    Date of Patent: June 20, 2017
    Assignee: The Feinstein Institute for Medical Research
    Inventors: Nicholas Chiorazzi, Rajendra N. Damle, Tarun Wasil
  • Patent number: 9683222
    Abstract: Chimeric ErbB ligand binding molecules having detectable binding activity for more ErbB ligands than any one of native ErbB1, ErbB3 or ErbB4 are disclosed. Preferably, the binding molecules bind a broad spectrum and, more preferably, the full spectrum of ErbB ligands. The chimeric ErbB ligand binding molecules generally have a subunit LI derived from one of Erb-B1, 3, or 4 and a subunit LII derived from another distinct ErbB receptor type. The sub-domain, SI, which joins LI and LII can be from either one of the receptor types or can have portions from both. Pharmaceutical compositions that contain the molecules and methods for the treatment of ErbB sensitive diseases are also disclosed.
    Type: Grant
    Filed: May 19, 2015
    Date of Patent: June 20, 2017
    Assignee: Ligacept LLC
    Inventor: Jason Hill
  • Patent number: 9650440
    Abstract: This invention relates to novel monoclonal antibodies that specifically bind to the alpha-folate receptor. In some embodiments, the antibodies inhibit a biological activity of folate receptor-? (FR-?). The antibodies are useful in the treatment of certain cancers, particularly cancers that have increased cell surface expression of the alpha-folate receptor (“FR-?”), such as ovarian, breast, renal, colorectal, lung, endometrial, or brain cancer. The invention also relates to cells expressing the monoclonal antibodies, antibody derivatives, such as chimeric and humanized monoclonal antibodies, antibody fragments, and methods of detecting and treating cancer using the antibodies, derivatives, and fragments.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: May 16, 2017
    Assignee: Morphotek, Inc.
    Inventors: Luigi Grasso, Nicholas C. Nicolaides, Philip M. Sass
  • Patent number: 9624297
    Abstract: This invention relates to novel monoclonal antibodies that specifically bind to the alpha-folate receptor. In some embodiments, the antibodies inhibit a biological activity of folate receptor-? (FR-?). The antibodies are useful in the treatment of certain cancers, particularly cancers that have increased cell surface expression of the alpha-folate receptor (“FR-?”), such as ovarian, breast, renal, colorectal, lung, endometrial, or brain cancer. The invention also relates to cells expressing the monoclonal antibodies, antibody derivatives, such as chimeric and humanized monoclonal antibodies, antibody fragments, and methods of detecting and treating cancer using the antibodies, derivatives, and fragments.
    Type: Grant
    Filed: July 9, 2009
    Date of Patent: April 18, 2017
    Assignee: Morphotek, Inc.
    Inventors: Luigi Grasso, Nicholas C. Nicolaides, Philip M. Sass
  • Patent number: 9574000
    Abstract: Anti-human B7-H4 antibody “6H3”, antigen-binding fragments, derivatives, and humanized variants thereof that are capable of immunospecifically binding to B7-H4, and the uses of such molecules in the diagnosis and the treatment of cancer and other diseases are disclosed. In preferred embodiments, the molecules are used to retard or prevent tumor growth, inhibit tumor-mediated suppression, eliminate tumors and/or deplete or block the activity of tumor-associated macrophages (“TAMs”) so as to alter their activity and/or decrease TAM-mediated immune suppression.
    Type: Grant
    Filed: December 19, 2013
    Date of Patent: February 21, 2017
    Assignees: MedImmune, LLC, The Johns Hopkins University
    Inventors: Solomon Langermann, Linda Liu, Sheng Yao, Lieping Chen, Michael Glen Overstreet
  • Patent number: 9567642
    Abstract: The invention relates to methods and related products for treatment and determining modes of treatment for cancer or prognosis of cancer. Preferably the methods are related to the induction of CD80 in p53 responsive cancer cells.
    Type: Grant
    Filed: February 1, 2013
    Date of Patent: February 14, 2017
    Assignee: Massachusetts Institute of Technology
    Inventors: David Feldser, Tyler E. Jacks, Leah Marie Schmidt
  • Patent number: 9561196
    Abstract: Provided is a method for evaluating test agents as candidates for treating prostatic diseases, including benign prostatic hyperplasia and androgen dependent and androgen independent prostate cancer. The method comprises providing a mouse comprising a human prostate primary xenograft, where the xenograft contains blood vessels that include human endothelial cells, initiating androgen deprivation in the mouse, administering to the mouse a test agent within a period of 1-7 days after initiating the androgen deprivation, and determining a reduction in human epithelial cells in the xenografts and/or a reduction in number of the endothelial cells or blood vessels in the xenograft. Also provided is a method for treating an individual for human prostate cancer or benign prostatic hyperplasia.
    Type: Grant
    Filed: September 12, 2011
    Date of Patent: February 7, 2017
    Assignee: Health Research, Inc.
    Inventors: Gary J. Smith, Howard M. Reisner, Danny R. Gray, Wendy Huss
  • Patent number: 9556256
    Abstract: P-Selectin on platelets and endothelium binds cell surface chondroitin sulfate (CS) proteoglycans, which are abundantly and stably expressed on the surface many cancer cells. Binding of the cancer cells through the CS moieties may be blocked to inhibit the interaction of cancer cells with platelets and endothelium. The present inventors disclose compositions and methods for the inhibition of cancer metastasis.
    Type: Grant
    Filed: April 5, 2012
    Date of Patent: January 31, 2017
    Assignee: The Board of Trustees of The University of Arkansas
    Inventors: Behjatolah M. Karbassi, Thomas Kieber-Emmons
  • Patent number: 9556249
    Abstract: The invention provides neuregulin antagonists and methods of using the neuregulin antagonists in delaying the time to tumor recurrence or preventing resistance of cancer cells to treatment with a therapeutic agent.
    Type: Grant
    Filed: February 17, 2011
    Date of Patent: January 31, 2017
    Assignees: Genentech, Inc., The Board of Trustees of the Leland Stanford Junior University
    Inventors: Erica Jackson, Eric Alejandro Sweet-Cordero
  • Patent number: 9545443
    Abstract: The present invention relates to methods of diagnosing and methods of treating hepatocellular carcinoma in a subject. The invention also relates to antagonists of PLVAP proteins, such as antibodies that specifically bind PLVAP proteins, as well as compositions and kits comprising antagonists of PLVAP proteins. The invention further relates to humanized antibodies that specifically bind PLVAP protein.
    Type: Grant
    Filed: July 18, 2014
    Date of Patent: January 17, 2017
    Assignee: China Synthetic Rubber Corporation
    Inventors: Kuo-Jang Kao, Andrew T. Huang
  • Patent number: 9533031
    Abstract: Disclosed are yeast-based immunotherapeutic compositions comprising mucin-1 (MUC1), as well as methods for the prevention and/or treatment of cancers characterized by the expression or overexpression of mucin-1 (MUC1).
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: January 3, 2017
    Assignees: GlobeImmune, Inc., The United States of America, as represented by the Secretary, Dept. of Health and Human Services
    Inventors: Alex Franzusoff, Zhimin Guo, Jeffrey Schlom, Kwong-Yok Tsang